Post by healthy11 on Oct 4, 2022 20:26:15 GMT -5
www.helpforadd.com/
Dr. Rabiner is a research psychologist at Duke University who studies ADHD, keeping up with new ADHD research that is published each month in the medical and psychology journals. The studies reviewed include research on promising new ADHD treatments, educational strategies for children with ADHD, how ADHD impacts development, and a variety of other issues. See the above link.
In his Oct. 2022 newsletter, he discussed a study about "How should ADHD treatment begin?"
The article starts, "Stimulant medication treatment and behavior therapy are currently the two child ADHD treatments with the strongest research support. However, when parents begin treatment for their child, or when professionals are initiating treatment with a new client, there is no research to guide the decision of which approach to begin with. Is it better to start with medication treatment and add behavior therapy if needed? Or, should behavior therapy come first with medication added if the child's response is not sufficient? Or, is it always preferable to begin with combined treatment? Does the order in which treatment begins even make a difference? Different professional organizations have published different recommendations on this issue but none are based on research that has directly examined these fundamental questions.
A study published several years ago in the Journal of Clinical Child and Adolescent Psychology [Pelham et al., (2016). Treatment sequencing for childhood ADHD: A multiple-randomization study of medication and behavioral interventions. Journal of Clinical Child and Adolescent Psychology. DOI 10:1080/15374416.2015.1105138] is the first to test whether ADHD treatment outcomes differ depending on whether medication or behavior therapy is tried first."
Dr. Rabiner goes over the study details, including who the participants were, how outcomes were measured, broad results, limitations and concerns, and he gives a summary and discusses practical implications of the study. It's worth signing up for his email newsletters at the link given at the top.
Dr. Rabiner is a research psychologist at Duke University who studies ADHD, keeping up with new ADHD research that is published each month in the medical and psychology journals. The studies reviewed include research on promising new ADHD treatments, educational strategies for children with ADHD, how ADHD impacts development, and a variety of other issues. See the above link.
In his Oct. 2022 newsletter, he discussed a study about "How should ADHD treatment begin?"
The article starts, "Stimulant medication treatment and behavior therapy are currently the two child ADHD treatments with the strongest research support. However, when parents begin treatment for their child, or when professionals are initiating treatment with a new client, there is no research to guide the decision of which approach to begin with. Is it better to start with medication treatment and add behavior therapy if needed? Or, should behavior therapy come first with medication added if the child's response is not sufficient? Or, is it always preferable to begin with combined treatment? Does the order in which treatment begins even make a difference? Different professional organizations have published different recommendations on this issue but none are based on research that has directly examined these fundamental questions.
A study published several years ago in the Journal of Clinical Child and Adolescent Psychology [Pelham et al., (2016). Treatment sequencing for childhood ADHD: A multiple-randomization study of medication and behavioral interventions. Journal of Clinical Child and Adolescent Psychology. DOI 10:1080/15374416.2015.1105138] is the first to test whether ADHD treatment outcomes differ depending on whether medication or behavior therapy is tried first."
Dr. Rabiner goes over the study details, including who the participants were, how outcomes were measured, broad results, limitations and concerns, and he gives a summary and discusses practical implications of the study. It's worth signing up for his email newsletters at the link given at the top.